Simultaneous determination of erlotinib and its major metabolites in human plasma using an isocratic liquid chromatography tandem mass spectrometry
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Poster
- By: ISHIDA, Takuya (Hamamatsu University School of Medicine, Hospital Pharmacy, Hamamatsu, Japan)
- Co-author(s): Naito, Takafumi (Hamamatsu University School of Medicine, Hamamatsu, Japan)
Suda, Takafumi (Hamamatsu University School of Medicine, Hamamatsu, Japan)
Kawakami, Junichi (Hamamatsu University School of Medicine, Hamamatsu, Japan)
Background: Erlotinib is a selective inhibitor of the epidermal growth factor receptor tyrosine kinase. The relations between the concentrations of its active metabolites, OSI-413 and OSI-420, and clinical response or adverse effect remain unclear. In earlier methods, the concentrations of these metabolites were determined as a total amount.
Aims: .. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.